Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Total Current Liabilities (2016 - 2025)

Agios Pharmaceuticals' Total Current Liabilities history spans 14 years, with the latest figure at $82.2 million for Q4 2025.

  • For Q4 2025, Total Current Liabilities rose 1.29% year-over-year to $82.2 million; the TTM value through Dec 2025 reached $82.2 million, up 1.29%, while the annual FY2025 figure was $82.2 million, 1.29% up from the prior year.
  • Total Current Liabilities reached $82.2 million in Q4 2025 per AGIO's latest filing, up from $74.8 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $119.5 million in Q3 2024 to a low of $45.1 million in Q1 2023.
  • Average Total Current Liabilities over 5 years is $65.3 million, with a median of $60.2 million recorded in 2021.
  • Peak YoY movement for Total Current Liabilities: crashed 52.55% in 2022, then soared 104.45% in 2024.
  • A 5-year view of Total Current Liabilities shows it stood at $59.8 million in 2021, then grew by 4.69% to $62.6 million in 2022, then grew by 8.5% to $68.0 million in 2023, then grew by 19.43% to $81.2 million in 2024, then grew by 1.29% to $82.2 million in 2025.
  • Per Business Quant, the three most recent readings for AGIO's Total Current Liabilities are $82.2 million (Q4 2025), $74.8 million (Q3 2025), and $70.4 million (Q2 2025).